Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVF-239
- Development stage
- Discontinued
- Lead developer
- BioVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BVF-239 is a proprietary, ready-to-use liquid formulation of caffeine citrate developed by BioVie (formerly NanoBiologics) for the treatment of apnea of prematurity (AOP). As a methylxanthine derivative, caffeine acts primarily as a competitive antagonist at adenosine A1 and A2A receptors. In neonates, this antagonism leads to the stimulation of the medullary respiratory center, increased minute ventilation, and an enhanced ventilatory response to hypercapnia. Additionally, caffeine improves diaphragmatic contractility and increases metabolic rate. BVF-239 was designed to offer a stable and convenient dosing option for the neonatal intensive care unit (NICU) setting, though BioVie has recently shifted its strategic focus toward other therapeutic areas, leaving the development of BVF-239 inactive.
- Other names
- caffeine citrateliquid caffeine
Beyond the preview
Go deeper on BVF-239.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVF-239.